ReviewPituitary2017
The role of combination medical therapy in the treatment of acromegaly.
Review in Pituitary, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results.Pituitary · 2021Trial
- Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study.European journal of endocrinology · 2020Trial
- Comprehensive design and characterization of pH-gradient-loaded donkey-milk exosomes for oral octreotide delivery: A bench-to-in silico roadmap.International journal of pharmaceutics · 2026Article
- Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE).Pituitary · 2024Article
- Aggressive and Metastatic Pituitary Neuroendocrine Tumors: Therapeutic Management and Off-Label Drug Use.Journal of clinical medicine · 2023Review
- Treatment Patterns, Adherence, Persistence, and Health Care Resource Utilization in Acromegaly: A Real-World Analysis.Journal of the Endocrine Society · 2023Article
- Giant growth hormone-secreting pituitary adenomas from the endocrinologist's perspective.Endocrine · 2023Article
- Validation of Myc-Associated Protein X (MAX) regulation in growth hormone secreting and nonfunctional pituitary adenoma.PloS one · 2023Article
- Growth hormone secreting pituitary adenomas show distinct extrasellar extension patterns compared to nonfunctional pituitary adenomas.Pituitary · 2022Article
- Temozolomide and Capecitabine Treatment for an Aggressive Somatotroph Pituitary Tumor: A Case Report and Literature Review.Frontiers in oncology · 2022Article
- Precision Therapy in Acromegaly Caused by Pituitary Tumors: How Close Is It to Reality?Endocrinology and metabolism (Seoul, Korea) · 2020Review
- Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly.Reviews in endocrine & metabolic disorders · 2019Review
- Updates in Diagnosis and Treatment of Acromegaly.European endocrinology · 2018Review
- Recent Progress in the Medical Therapy of Pituitary Tumors.Endocrinology and metabolism (Seoul, Korea) · 2017Review
- Review
- Active postoperative acromegaly: sustained remission after discontinuation of somatostatin analogues.Endocrinology, diabetes & metabolism case reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeUncontrolled acromegaly results in approximately 2-fold excess mortality. Pituitary surgery is first-line therapy, and medical treatment is indicated for persistent disease. While cabergoline and pegvisomant are used in select patients, somatostatin receptor ligands (SRLs) remain the cornerstone of medical treatment. Management of patients poorly responsive to SRLs is therefore, challenging. The purpose of this review is to highlight the options for combination medical therapy in the treatment of acromegaly, with an emphasis on efficacy and safety.
methodsAll original articles/abstracts detailing combination medical therapy in acromegaly were identified from a PubMed search.
resultsStudies reviewed included retrospective and open-label prospective studies. While the combination of SRL and cabergoline was generally well tolerated, a lower baseline insulin-like growth factor-1 (IGF-1) level was the best predictor of efficacy; this combination may be most effective in patients with mildly elevated IGF-1. SRL-pegvisomant combination normalized IGF-1 in the majority of patients; continued efficacy despite individual drug dosing reduction was also reported. The risk of significant liver enzyme elevation was, however, higher than that reported with SRL monotherapy; close monitoring is recommended. Data on pegvisomant-cabergoline combination is limited, but this may be an option in the setting of SRL intolerance. Reports on temozolomide used in combination with other medical therapies in patients with aggressive GH-secreting tumors are also summarized.
conclusionWhile more prospective, randomized controlled trials on long-term efficacy and safety are needed, combination medical therapy remains a treatment strategy that should be considered for acromegaly patients poorly responsive to SRLs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.